RHOB and melanoma: Mechanistic studies revealed that RhoB modulates the response of melanoma cells in vitro to PLX4032, a different BRAF kinase inhibitor, via the AKT pathway and combination of an AKT inhibitor with PLX4032 in vivo reversed RhoB-mediated resistance to PLX4032.